Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323674 | 0.86 | LTA4H (0.59) | TSHRLTA4H | |
| SCHEMBL17442409 | 0.85 | LTA4H (0.58) | TSHRPOLBKDM4ESMN1; SMN2LTA4H | |
| SCHEMBL228313 | 0.85 | LTA4H (0.58) | TSHRPOLBKDM4ESMN1; SMN2LTA4H | |
| SCHEMBL31436855 | 0.84 | HTR1B (0.53) | MAPTPOLBKDM4ESIGMAR1LTA4H | |
| SCHEMBL31210089 | 0.82 | LTA4H (0.46) | ALDH1A1MAPTKDM4ESIGMAR1LTA4H | |
| SCHEMBL29036808 | 0.82 | ATM (0.51) | TSHRALDH1A1POLBKDM4ESIGMAR1 | |
| SCHEMBL55617 | 0.82 | SIGMAR1 (0.48) | TSHRALDH1A1POLBKDM4ESIGMAR1 | |
| SCHEMBL29769807 | 0.82 | SIGMAR1 (0.48) | TSHRALDH1A1POLBKDM4ESIGMAR1 | |
| SCHEMBL15520988 | 0.82 | SIGMAR1 (0.48) | TSHRALDH1A1POLBKDM4ESIGMAR1 | |
| SCHEMBL26690765 | 0.82 | LTA4H (0.46) | ALDH1A1MAPTKDM4ESIGMAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| EP-0966464-B1 | SUBSTITUTED 2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6114330-A | BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0966464-A1 | SUBSTITUTED 2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998039328-A1 | SUBSTITUTED 2,4-DIAMINOPYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2, RRM2B | TSHR 1009/4885ALDH1A1 2294/4885MAPT 1804/4885 |
| US-20070191394-A1 | Antibacterial agents | MRPL21, RPN2, FBL | TSHR 4486/4885ALDH1A1 637/4885MAPT 4424/4885 |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | DPYD, TYMP, ITPA | TSHR 3932/4885ALDH1A1 272/4885MAPT 4632/4885 |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CYP51A1, ERG28, CYP3A7 | TSHR 3394/4885ALDH1A1 1486/4885MAPT 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.